Business Wire

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the ...
Nasdaq

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary ...
Detroit News

Dr. Roach: Understanding how systemic lupus affects a person's body

Dear Dr. Roach: What is lupus, and what does it do to your body? I just had a friend diagnosed with it after many months of tests. — T.S.B. Dear T.S.B.: The term "lupus" generally means systemic lupus ...
Business Wire

EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus ...

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, ...